Over 50 combined years of medical practice and product innovation
Evan C. Unger, MD, FACR
Interim Chief Executive Officer
Evan Unger M.D. is a renowned expert on ultrasound contrast media. He founded MVT to advance the field of ultrasound contrast agents and theranostics. Dr. Unger has also founded three other biotech companies. His first company, ImaRx Pharmaceutical, developed 3 FDA approved drugs, including Definity®, the world’s #1 selling ultrasound contrast agent. ImaRx Pharmaceutical was acquired by DuPont yielding a > 20x ROI. Dr. Unger’s second company, ImaRx Therapeutics, went public and performed clinical trials using ultrasound and microbubbles to treat ischemic stroke. Dr. Unger co-founded NuvOx, a clinical-stage biotech company that is in Phase II trials for stroke and brain cancer. He is a co-inventor on the issued U.S. patent covering MVT-100 and also an inventor on over 120 other issued US patents. He is a board-certified radiologist and has had an appointment as a Professor of Radiology and Biomedical Engineering at the University of Arizona and serves as President and CEO of NuvOx Pharma.
Emmanuelle J. Meuillet, PhD
Chief Operating and Scientific Officer
Emmanuelle J. Meuillet is an accomplished scientist, inventor and entrepreneur focusing on drug discovery and development. Dr. Meuillet obtained a PhD in Biochemistry and Pharmacology from the Louis Pasteur University (France). She has had an appointment as an Associate Professor at the University of Arizona. Over the years, Dr. Meuillet has managed many NIH funded programs in oncology and experimental therapeutics. She is an experienced manager of national and international multidisciplinary innovative projects. She founded two biotech companies, PHusis Therapeutics, Inc. in 2009 and Theraxen Technologies, LLC in 2016 advancing the development of small molecules. Dr. Meuillet is a consultant for the NIH and DoD. She is the author of more than fifty peer reviewed manuscripts and reviews, she is an inventor on five patents and she belong to several editorial boards for specialized cancer journals. She joined Microvascular Therapeutics in 2018.
Wyatt Unger, MD, MBA
Chief Medical Officer
Dr. Unger received his B.A. in economics from Northwestern University, M.D. from the University of Arizona College of Medicine with Alpha Omega Alpha honors, and MBA from the University of Arizona Eller College of Business. Dr. Unger completed diagnostic radiology residency training at Arizona, where he also completed a fellowship in Abdominal MRI imaging. Dr. Unger has authored multiple peer-reviewed abstracts and journal publications, worked as a consultant in clinical development and clinical trial design for Nuvox Pharmaceutical and serves as the Chief Medical Officer for Microvascular Therapeutics where he is overseeing clinical development and clinical trial design for their pharmaceutical candidate MVT-100.
Chief Medical Officer
Marty Rosenberg, MD
Dr. Rosenberg is a graduate of Temple University School of Medicine and trained in general surgery at Albert Einstein Medical Center in Philadelphia. He joined Squibb Diagnostics in 1990 and worked on the clinical development and approval of two novel oral contrast agents from ImarX pharmaceuticals: SonoRx and LumenHance. In 1996, he was hired by Bristol-Myers Squibb Medical Imaging, formerly DuPont Pharma, to develop the ultrasound contrast agent Definity (DMP-115), also invented by Imarx pharmaceuticals. Dr. Rosenberg is currently working for Bayer Radiology where he led the initial approval and additional indications for Gadavist in the US.
David Lim, BS, MBA
Director of Finance
David received a Bachelor of Science degree from Rutgers University, and an MBA from NYU Stern School of Business. David has extensive experience in financial markets both public and private, and asset management industry. He Co-Founded Washington Square Capital, which focuses on making acquisitions of privately held businesses. Previously, he worked as a trader for a subsidiary of Royal Bank of Canada, with $40B in assets under management by the time David left the firm. His experience also includes being a proprietary trader. As a trader, David researched and developed investments to be implemented for the firm’s portfolios and funds, while mitigating risk. In addition to his finance experience, David has advised on transactions for commercial real estate in New York City. He has played a critical role in the due diligence process for several investments. He is currently an Advisor for a Web 3 company Plato.